Minerva Neurosciences (NERV) Long-Term Investments (2015 - 2017)
Minerva Neurosciences posted quarterly Long-Term Investments of $5.0 million for Q4 2017, down 51.49% on a QoQ basis from $10.4 million in Q3 2017.
Minerva Neurosciences (NERV) has 2 years of Long-Term Investments data on file, last reported at $5.0 million in Q4 2017.
- For the quarter ending Q4 2017, Long-Term Investments changed N/A year-over-year to $5.0 million; the trailing twelve-month figure through Dec 2017 stood at $5.0 million (changed N/A YoY), and the FY2017 full-year result was $5.0 million, changed N/A from the prior year.
- Long-Term Investments for Q4 2017 stood at $5.0 million, down from $10.4 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $10.4 million in Q3 2017 and bottomed at $1.4 million in Q3 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 5.02 Mn |
| Sep 30, 2017 | 10.36 Mn |
| Sep 30, 2015 | 1.41 Mn |
| Jun 30, 2015 | 9.44 Mn |